Showing results (231-240 of 900) with videos related to

Sort By:
Pageof 90
International Journal of Cancer|January 3, 2013
Is acute myeloid leukemia a liquid tumor?Maro Ohanian, Stefan Faderl, Farhad Ravandi, et al.
Leukemia|June 16, 2021
Therapeutic implications of menin inhibition in acute leukemiasGhayas C Issa, Farhad Ravandi, Courtney D DiNardo, et al.
International Journal of Hematology|April 3, 2009
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experienceArturo Vega-Ruiz, Stefan Faderl, Zeev Estrov, et al.
Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
American Journal of Hematology|July 31, 2016
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyNicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.
Cancer|March 9, 2023
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulationDaniel Nguyen, Hagop M Kantarjian, Nicholas J Short, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 9, 2026
Comprehensive Cytogenomic Profiling of T-Lymphoblastic Leukemia by Optical Genome Mapping, Karyotyping and Next Generation SequencingGuilin Tang, Alexandra Reynolds, Farhad Ravandi-Kashani, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
Pageof 90